Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 184Gastrointestinal 75CNS 27Genitourinary 19Head & Neck 17Tumor-Agnostic 16Breast 16Sarcoma 13Gynecologic 8Other solid neoplasm 4Other hematologic neoplasm 4Myeloid 3NET 2Endocrine 2Dermatologic 2Plasma cell 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Acute 2Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 414Cytarabine 336fludarabine phosphate 231Rituximab 206Methotrexate 198fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 112Melphalan 110Dexamethasone 109Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Antilymphocyte Serum 91Daunorubicin 90Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 70Prednisone 68Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Erlotinib Hydrochloride × Other hematologic neoplasm × Clear all
NCT01174043 2023-10-13

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Indiana University

Phase 2 Completed
11 enrolled 8 charts
Other hematologic neoplasm

Leukemia, Myelomonocytic, Acute

NCT01664897 2020-01-07

Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
29 enrolled 11 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Incyte Corporation

Phase 2 Withdrawn
Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

NCT00977548 2013-09-16

Erlotinib Study for Myelodysplastic Syndrome (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 10 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡